RxDoctor Payments DataLook up a doctor →

Adrian Lavina, MD

Retina Specialist · Palm Beach Gardens, FLNPI 1447279609

Payments from drug & device makers

$325,976in general payments, 2019–2025

Across 316 payments — averaging $1031.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$279K
  • Astellas Pharma Global Development$30K
  • AbbVie$7K
  • US Retina LLC$3K
  • Regeneron Healthcare Solutions, Inc.$2K
  • Astellas Pharma US Inc$918
  • plus $5K from 21 others
$762in research payments, 2019–2025

Across 6 payments — averaging $127.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$762

What the payments were for

  • Consulting fees$5,25030%
  • Travel & lodging$3012%
  • Food & beverage$9,14852%
  • Ownership interest$2,99717%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$325,976 in reported general payments places this provider in the 85th percentile of 118 retina specialist providers in Florida.

See all retina specialist providers in Florida

Medicare billing

Part B allowed, 2024
$4,559,303
Medicare patients
1,128
Services billed
63,515

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProlensaBromfenac Sodium36$12,778
Bromfenac Sodium38$5,396
Prednisolone Acetate112$4,332
MoxifloxacinMoxifloxacin Hcl63$1,364
Ketorolac Tromethamine56$1,020
ErythromycinErythromycin Base44$422
Dorzolamide Hcl25$322
Timolol Maleate14$95
Brimonidine Tartrate11$33

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$22$12,77836 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 118 retina specialist providers in Florida.

Other retina specialist in Palm Beach Gardens

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →